Despite the significant benefits brought by the neoadjuvant treatment regimen combining trastuzumab and pertuzumab (HP) for HER2-positive breast cancer patients6, there remains a proportion of 30% to 60% who fail to achieve pathological complete response (pCR) following neoadjuvant chemotherapy combined with HP6-8. This evidence concerns the gene ERBB2 and breast carcinoma.